Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
Biocartis has priced their cartridges at a point where there is room for the clinic or hospital to mark it up and receive reimbursements from the insurers. With the 510(k) pathway approval, point of care users will make a nice profit off the use of Idylla. That combined with the fast turn around time will greatly expedite adoption of the platform. FL
Flatlander schreef op 2 maart 2019 17:24 :
Biocartis has priced their cartridges at a point where there is room for the clinic or hospital to mark it up and receive reimbursements from the insurers. With the 510(k) pathway approval, point of care users will make a nice profit off the use of Idylla. That combined with the fast turn around time will greatly expedite adoption of the platform.
FL
Je beweert dus dat Biocartis veel te weinig geld vraagt voor het gebruik van Idylla-cassettes zodat het ziekenhuis er veel winst mee kan maken...!!!?? Dat zou betekenen dat Biocartis over 10 jaar nog geen winst maakt.
I listened to a Podcast called "Megatrends" a couple weeks ago. I'm pretty sure that the Dec 10 episode is discussing Biocartis as one of the small companies with big healthcare potential. Oppenheimer is one of the larger institutional investors in Biocartis. FL
In the U.S the insurance reimbursement rates are determined by the specific genomic pathway panel being analyzed (BRAF, KRAS etc). The reimbursement rate will not be influenced by whether it is analyzed by a NGS method in a lab vs. an IVD test in the clinic where the biopsy is taken. Because Idylla's competitors are largely lab based with greater technician effort, reagents, steps etc. the competitors currently have much higher costs. Biocartis has chosen to initially price at a reasonable margin that puts the assay cost well below competitors. This leaves the clinical lab where the Idylla test is run the potential to mark up the costs considerably and still receive full insurance reimbursement. I believe that ones the 510(k) pathway approvals are received that the adoption rates will take off in the US since the clinics will have a strong economic reason to use the test (i.e., they can bill it out for 100% profit). It remains to be seen how Biocartis will change the cartridge billing rate once 501(k) approval is received for clinical diagnostic use. Arguably, they should increase the price. FL
Biocartis is currently getting little credit (based on share price doldrums) for several positive developments including: expansion of GHDX partnership into Urology; China and Japan market expansion; Product offering expansion in MSI; AstraZeneca CDx partnership Many of these deals allow Biocartis to leverage limited resources by having their partner carry some of the regulatory burden. This is important now when profitability is still a couple of years off. At times I'm frustrated that BCART has not listed in the US. Looking at how GH has performed since it IPO'd, I believe that BCART could raise a lot more cash with less dilution. I've convinced myself that this is balanced by the advantage that they are currently flying under the radar building momentum (increased product offerings, geographic expansion) without a huge target on their back. Too much visibility on the NYSE or Nasdaq would undoubtedly draw competitors. At some point I'm sure BCART will list in the US (at least it seems to be the trail that QGEN and others have taken). In the mean time BCART generated good technical reviews. I was impressed by the attached link that suggested Idylla has a place for 1st line diagnostic pathology. Placement in this setting (clinics, hospitals, small labs, etc.) would be allow huge expansion. This is obviously dependent on expanding beyond the RUO designation, That's why the emphasis on 510(k) pathway approvals are critical. jcp.bmj.com/content/71/9/757 FL
Anyone on the board have any thoughts on the China joint venture with Wondfo. Will the intellectual property be protected adequately? FL
Flatlander schreef op 6 maart 2019 15:27 :
Anyone on the board have any thoughts on the China joint venture with Wondfo. Will the intellectual property be protected adequately?
FL
I think the wondfo JV will prove to be very successful in the future: China is a country where due to pollution there is a high incidence of cancers. Alligning the cartridge portfolio to these types of cancers can in my perspective open a huge market potential. I also think that Biocartis and its CEO are smart enough to be aware of the potential risk of intellectual property breaches. By choosing Wondfo as their partner, they choose a market leader in China who is also active in the US (lab in San Diego and brancg in Chicago), and in 120 countries in total. They are seen as a trustworthy partner.
Thanks, I agree with your assessment of the market potential. I hope you're right on the trustworthiness of Wondfo. When I first invested in Biocartis, I tried to research the patent portfolio. I recall that they have approximately 40 patents and license agreements protecting various aspects of their technology. Of course, this all depends on a legal system that is willing to enforce intellectual property rights. I was a bit disappointed with the year end results but was pleased with the initiatives identified for 2019. I believe the ramp up in the U.S. is constrained because of the RUO designation. The sales reps have to be very careful not to cross the line in marketing it as a clinical diagnostic device. I'm always intrigued by the potential for Idylla to be used to disseminate partner sponsored ads and educational material. Idylla is in effect a very valuable ecosystem that is positioned to dispense valuable information at the time of biopsy or genetic pathway diagnosis. The placement of such information or ads at such a pivotal time in the patient treatment is invaluable and could make BCART a preferred partner for CDx relationships. This is all a ways off, and BCART needs to ramp console placement and cartridge volumes before entertaining any partner sponsored ads. I'm glad I finally found a forum to discuss Biocartis. FL
Anyone know the status of the Immunexpress -Biocartis relationship? The attached article suggests that Immunexpressis rounding up additional funding to advance the Septicyte IVD Assay.https://www.genomeweb.com/molecular-diagnostics/immunexpress-wins-745k-hhs-contract-rapid-sepsis-assay#.XIGYTCJKjIW However, I don't recall any mention of it on the Feb 28 update. Furthermore, the following statement on page 4 of the Feb 28 Press Release leads me to believe that Biocartis is terminating the ImmunExpress collaboration. "Contract terminations – During H2 2018, a review of infectious disease oriented collaborations and license agreements was conducted, which resulted in the termination of certain collaborations that were no longer of strategic importance to Biocartis. As part of this review, the agreement with Koninklijke Philips N.V., under which Biocartis had gained access to certain patent rights and know-how, in relation to an ancillary platform for selective enrichment of pathogen DNA for use with bloodstream infection tests, has been terminated. The underlying patent rights are being returned to Philips and the related book value has been fully impaired, resulting in EUR 3.2m non-cash impairment. The ImmunExpress relationship appears to have existed for several years (+/- 2012 -six years before last years announcement) but does not appear to be advancing. www.debiopharm.com/debiopharm-innovat... Other than strategic decision to emphasize oncology related assays for business/cost related reasons,, is there another factor that has limited progress on the septicyte IVD assay? The fact that this has been kicking around for so long makes it look like some type of technical constraint. FL
Good news on the CDx collaboration with Bristol Myers for MSI. I used to get upset that BCART was operating totally under the radar in the US. Now I'm thinking it may be a strategic advantage. They have been able to secure CDx agreements with 5 major pharma companies,, launched Idylla in every major market in the world and are in the process of validating the GHDx Oncotype Dx Breast IVD assay (only test shown to predict whether a patient will benefit from Chemotherapy). If the OncoType prostate test is half as strong an assay this could be a very long running profitable collaboration. These collaborations are coming to BCART without drawing a number of copycat oncology IVD competitors. Like they have said in many of the conference calls, this is a multiyear journey. I've switched to using these benchmarks to track progress rather than focusing on the share price, FL.
Thank you for this information.
Thanks. I'm not trying to monopolize the posts on this board. I see a lot of potential for BCART and I've been looking for a forum to discuss the company. Outside of IVD oncology competition (does not currently seem to be a concern), the major risk seems to be that NGS may get cheaper and faster in the future. That is fine, I believe that is still a ways off. There will always be a need for timely information at the time of biopsy/diagnosis. FL
The China IVD registration process appears complex. The extent to which validation studies conducted in foreign markets may be utilized to support the registration is unclear. Once registered, the IVD test is generally not reimbursed by insurance for a period of 2 years. During this time the patient bears the cost for the test. The attached article does provide a perspective on the immense potential of the China IVD market. Looks like we should be prepared for this to play out in a 3 to 5 year time frame. FLwww.pacificbridgemedical.com/publicat...
This statement is encouraging: "While all Class II and III IVDs have been required to go through local clinical studies in China, China’s State Council recently issued new regulations on October 8, 2017 that should allow some foreign clinical trial data for medical device and IVD registration. Trials must be conducted at multiple centers and meet CFDA registration requirements. These changes should be positive for Western medical device manufacturers, reducing the need for local clinical trials, lowering market entry costs, and cutting the time needed to achieve registration. Avoiding the need for a local clinical trial could reduce the IVD registration timetable by about one year. What remains unclear is which IVD products will be able to use data from foreign clinical trial data." If this plays out favorably, might it be possible to launch sales of of some assays (i.e., Iung CRC) late this year? The cartridges and consoles would need to initially be imported from Belgium until local manufacturing is established. Just conjecture. FL
ze hebben het echt moeilijk om over de 11.8 te gaan blijkbaar ... Blijkbaar niet veel momentum op dit ogenblik.
Based on today's weakness, it looks like Biocartis might revisit the 52 week lows in the 9's. It got absolutely no traction from the BMY CDx collaboration announcement. I see a variety of late 2019-2020 catalysts but probably not a lot in the near term. Possible catalysts include: 1) A press release from Wondfo (China Partner) or Nichirei Bioscience (Japan Partner) indicating progress with registration and providing a launch date would be a major catalyst. I understand that the Wondfo collaboration will include manufacturing in China. However, why must this preclude launching with cartridges a consoles manufactured in Belgium while the China manufacturing facility is being constructed; 2) Information on the Onco Dx Breast assay validation and specifically when EU approval might be expected will be major news. 3) Similarly, the Onco Dx prostate status will also be welcome news since both of the OncoDx products will serve large markets in the EU and US. 4) Finally, updates on the status of FDA negotiations for approvals of MSI, BRAF, KRAS etc would probably be the biggest momentum maker since this would allow the product to be used for diagnostic purposes rather than RUO. Such an authorization would allow the tests to be reimbursed by insurers. This would undoubtedly allow the sales to ramp in the US. One of the things I like most about BCART is that they can leverage the staff and technical resources of their partners (CDx Pharma and content partners like GHDX) to expedite FDA approvals. If FDA makes progress revamping the 510K pathway, I don't see why some of these approvals might not move faster than the guidance. I think the FDA process will eventually get to where the EU Marking procedure has gotten (i.e., about 6 months from filing to approval), but this will likely take a few years. In the short term, my best guess is that BCART could go as low as 9.7 and will probably have difficulty breaking 12 without one of the aforementioned catalysts. I've pretty much loaded up, but I may add a little more to my share count. Any-one know the reason for the apparent downgrade by one of the analysts? FL
I think the price of Biocartis share price has been dragged down by low growth expectations for Europe. The German Bund yields went negative again suggesting that the overall market sees little potential for growth in Europe. Perhaps this macro view is related to the uncertainty over Brexit. I don't think any of this affects the opportunities for BCART. Three years from now, we will probably look back at this period being critical. BCART is expanding offerings and is moving toward diagnostic approvals in the U.S. The switch from RUO will allow greater sales in the U.S.. Also, BCART has wracked up 4 CDx agreements without garnering much attention. They have established international distribution partnerships with Fischer Healthcare, Wondfo and Nichirei Bioscience without competition placing a target on their back. I believe that even the current US trade war with China may also be benefiting BCART by limiting US competition (primarily lab based NGS) from making headway in China. BCART is working with limited funds and therefore must proceed cautiously. A large competitor could throw money and try to make up lost ground quickly. This could quickly erode BCARTs head start advantage. GHDX has been successful by developing assays that anticipate trends. They have targeted questions that are critical during treatment (i.e., will this woman benefit from chemotherapy, is this man's prostate cancer likely to turn aggressive?). They now have prioritized answering these questions through an IVD platform, so the results are available cheaper, quicker, without sending out tissue samples, etc.). I waited about 3 years for the market to recognize the value in GHDX (an eventual triple). This only occurred after the TailorX release at ASCO last year. GHDX had published numerous similar studies results before the TailorX results were published in the NEJM. It often takes a high profile large study in a reputable journal to make a difference. BCART is building out critical offerings, infrastructure and relationships before they have a big target on their back. I believe that their partners will help with regulatory approvals and eventually author or co-author papers that will speed adoption rates. This all takes time. MDx and CDx are in their infancy. Most hospitals and clinics have not developed standardized approaches yet. This trend will likely play out over a decade or more. In the meantime we will need to be patient. Given the progress outlined above, it's hard to believe that BCART still trades below the 2015 IPO price. FL
Apparently the Septicyte assay on Idylla is not dead yet. Immune express announced in Early Feb that they had raised additional funds for the program. The infectious disease IP that Biocartis returned to Phillips must have been unrelated. That said, BCART has downplayed this program (I don't even think the partnership is mentioned on any recent Investor Relations info). I stand by my earlier statement that their must be a difficult technical constraint since it is costing more and has been under development for so long.immunexpress.com/newsroom/ FL
Cellgen to develop IVD oncology assays. Looks like they are about 4 years behind BCART.www.genomeweb.com/molecular-diagnosti...
Tijd voor nog eens een persbericht: bedrijf blijft naar mijn inzien ondergewaardeerd en koers volgt de recente uptrend van de markt momenteel nog niet ...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee